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Soft tissue sarcomas (STS) are rare, malignant tumors of mesenchymal origin 
that manifest in the connective tissues, including muscle, adipose and deep skin tissue, 
nerves, and joint tissue.   Complications from primary or recurrent sarcomas often lead to 
increased morbidity, but the most lethal aspect of sarcomas is their propensity for 
hematogenous dissemination leading to metastatic disease.  After development of distant 
metastases, the median survival for patients with STS is merely 11 to 15 months1,2.  
Therefore, gaining a better understanding of the metastatic environment is essential to 
developing new therapies.  The tumor microenvironment  has been implicated as an 
essential component for metastatic progression and one of the most prominent cell types 
of the tumor microenvironment is the cancer-associated fibroblast (CAF)3,4. CAFs promote 
tumor progression by stimulating angiogenesis, cancer cell growth, invasion and 
metastasis, and through evasion of the immune response5,6.  Studies clearly show the 
importance of CAFs in tumor advancement; however, their origins have not been 
conclusively determined, although multiple origins have been proposed7–12. Studies 
previously conducted in our lab have demonstrated that hematopoietic stem cells (HSCs) 
are a novel source for CAFs and their precursors in the blood, circulating fibroblast 
precursors (CFPs)13. Our lab has further shown that murine CFPs are present in 
peripheral blood, found in vivo in the tumor stroma, increase with tumor development, and 
contribute to tumor growth, suggesting that CFPs play a direct role in promoting the 
progression of solid tumors14. Additionally, studies from our lab revealed a HSC origin for 
human CFPs15. The function of human CFPs in tumor metastasis, specifically STS, 
however, has yet to be established.  
Therefore, the goal of this study was to evaluate the peripheral blood of patients 
with STS in order to characterize CFPs in these patients and determine 
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their role in promoting STS metastatic progression. In this study, peripheral blood was 
collected from patients with STS and from normal control subjects. Our data has shown 
that CFPs are present within the peripheral blood of patients with STS and normal control 
subjects and that these cells display markers of fibroblasts, including collagen 1, alpha 
smooth muscle actin, and vimentin.  Our data have also shown that although there is no 
significant difference in average number of CFPs present within the peripheral blood of 
STS patients compared to normal control, evaluating individual results indicated that 
patients with metastatic disease who are not on chemotherapeutic treatment may have 
increased numbers of CFPs. We further showed that CFPs from patients with STS 
contribute to sarcoma cell proliferation, migration, and invasion in vitro and that in vitro 
generated tumor-exposed CFPs showed enhanced ability to contribute to sarcoma 
invasion and displayed an altered cytokine profile when compared to control CFPs.  Our 
data indicate CFPs may play an important role in tumor progression and that through 
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Chapter 1: Introduction 
Section 1: Soft Tissue Sarcoma  
 
1.1 Epidemiology and Etiology 
Soft Tissue Sarcomas (STS) are rare, malignant tumors of mesenchymal origin.  
They constitute 12% of pediatric cancers, but only 1% of all adult malignant neoplasms, 
with a slight male predominance16,17.  Three-fourths of STSs can be classified as either 
undifferentiated pleomorphic sarcoma, liposarcoma, leiomyosarcoma, 
myxofibrosarcoma, synovial sarcoma, or malignant peripheral nerve sheath tumor 
(MPNST)18. It is estimated that 11,930 new cases of STS will be diagnosed in 2015, 
along with 4,870 deaths19. The incidence according to age varies: embryonal 
rhabdomyosarcoma occurs predominately in the pediatric population, while synovial 
sarcoma occurs mostly in young adults, and undifferentiated pleomorphic sarcoma, 
liposarcoma, leiomyosarcoma, and myxofibrosarcoma tend to occur in the elderly.  In 
similarity with other malignant tumors, the rate of adult STS increases with age- the 
median diagnosis being around 65 years17. 
Although the etiology of many soft tissue sarcomas is unknown, chemical 
carcinogens, radiation, viral infection and immunodeficiency, or genetic susceptibility 
have been associated with tumor development. Some studies have indicated there is 
increased incidence of STS in those exposed to chlorophenols, phenoxyacetic 
herbicides, and dioxin20,21. Other reports suggest breast cancer patients exposed to 
radiation treatments are at increased risk of developing post-irradiation sarcoma22. 
Additionally, patients with the retinoblastoma gene (RB1) germline mutation are at 
elevated risk for STS (leiomyosarcoma, malignant fibrous histiocytoma, 
rhabdomyosarcoma, and liposarcoma) with statistically significant increases in STS in 
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patients treated with radiation, with the majority of STS occurring in the radiation field 
after exposure23.  Viral infection and immunodeficiency play a prominent role in the 
development of Kaposi sarcoma, which is clinically linked to Human Herpes Virus 8, a 
gamma-herpes virus found to contain genes involved in evading the normal immune 
response24,25.  Genetic susceptibility is also known to be associated with elevated risk of 
STS.  Li-Fraumeni syndrome, an autosomal dominant disease caused by germline 
mutations of the TP53 tumor suppressor gene predisposes individuals to the 
development of primary tumors at a young age.  A study of 200 Li-Fraumeni syndrome 
family members revealed that 17% of their primary cancers were diagnosed as STS26. 
As stated previously, the retinoblastoma gene (RB1) is also associated with increased 
risk of STS.  Neurofibromatosis 1, an autosomal dominant disease caused by mutations 
in the NF1 gene has been linked to certain STSs, including malignant peripheral nerve 
sheath tumors, of which 50% have the NF1 mutation27. 
 
1.2 Histopathology 
Soft Tissue Sarcomas (STS) are an extremely diverse group of tumors- according to 
the World Health Organization they comprise more than 100 different histological 
subtypes17. STSs are classified according to their presumed origins and the diagnosis of 
STS is based upon morphology along with immunohistochemical (IHC) staining. In 
addition to IHC staining, Fluorescence In Situ Hybridization (FISH) is often used to 
identify subtypes of STS containing chromosomal translocations, which one third of all 






Table 1.1 Soft Tissue Sarcoma Translocations 
Diagnosis Chromosomal Abnormality Genes Involved 








Alveolar soft part sarcoma t(X;17)(p11.2;q25) TFE3-ASPL 














































Common IHC stains include desmin to identify rhabdomyosarcoma and 
leiomyosarcoma (as one of multiple markers). S100 positivity correlates with cells arising 
from the neural sheath and Factor VII identifies tumors of endothelial origin.  Cytokeratin 
staining can distinguish between synovial sarcoma and epithelioid sarcoma (both stain 
positive) and fibrosarcoma (stains negative).  While some markers are more 
characteristic than others, it is often necessary to examine a spectrum of markers in 
order to determine histologic subtype. 
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 As stated above, the most frequent subtypes of STS include: undifferentiated 
sarcoma, liposarcoma, leiomyosarcoma, myxofibrosarcoma, synovial sarcoma, and 
malignant peripheral nerve sheath tumor, all of which have distinct characteristics. 
Undifferentiated sarcoma, previously called malignant fibrous histiocytoma, is the most 
common subtype of STS. This subtype refers to sarcomas that lack specific lines of 
differentiation and may be further divided into pleomorphic, round cell, and spindle cell 
variants. Liposarcomas are believed to be derived from precursors of adipocytes and are 
commonly found in the extremities and retroperitoneum.  The three main subgroups of 
liposarcoma are well-differentiated/dedifferentiated, myxoid/round cell, and pleomorphic. 
Myxoid liposarcomas typically reveal a FUS-CHOP or TLS-CHOP translocation28,29. 
Well-differentiated/dedifferentiated almost invariably express diffuse nuclear MDM2 
and/or CDK4, whereas pleomorphic liposarcomas are negative for expression30. 
Leiomyosarcomas show pure smooth-muscle differentiation and are found in the 
retroperitoneum, veins, and uterus. Synovial sarcomas histologically resemble synovial 
cells, however their origin is unknown. Synovial sarcomas are characterized by 
translocations of the SYT gene on chromosome 18 to SSX1, SSX2, or SSX4 on the X 
chromosome31. Lastly, MPNST are commonly found in the trunk, extremities, head, and 
neck. Diagnosis is difficult due to varied histomorphology and although S100 positivity is 
often found, it is not uniformly expressed. 
 
1.3 Clinical Presentation 
STS manifests in the connective tissues (striated skeletal and smooth muscle, 
tendons, adipose tissue, fibrous tissue, blood vessels, peripheral nerves, and the lining 
of the joints) and often presents as a gradually enlarging, painless mass.  While some 
patients complain of pain or edema in an extremity due to compression by the tumor 
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mass, it is rare for a patient to present with constitutional symptoms of fever or weight 
loss. STSs most prevalently occur in the extremities (75%), followed by the trunk wall 
(10%), and the retroperitoneum (10%). These tumors have the capacity to become quite 
large, particularly in the thigh and retroperitoneum, and growth rates vary depending 
upon tumor aggressiveness.  Their common pattern of spread is hematogenous, 
predominately to the lung, whereas spread to regional lymph nodes is infrequent, 
excluding a few histological subtypes (rhabdomyosarcoma, synovial sarcoma, epithelioid 
sarcoma, clear cell sarcoma, and the vascular sarcomas)32,33.   
 
1.4 Diagnosis, Grading, and Staging 
Due to their rarity and usually asymptomatic presentation, STSs tend to be initially 
misdiagnosed, exacerbating their malignant potential. Further causation of diagnostic 
and therapeutic challenges is the heterogeneity of these tumors, which are comprised of 
more than 100 different histological subtypes17. Because STS is rare and often 
unsuspected, multiple diagnostic tests should be performed to verify presence of STS. 
To distinguish between a benign soft tissue mass and STS, the United Kingdom 
Department of Health published criteria for urgent referral of patients with soft tissue 
lesions.  The criteria includes a soft tissue mass greater than 5 cm, painful lump, lump 
that is increasing in size, a lump of any size that is deep to the muscle fascia, or 
recurrence of a lump after previous excision34.  After referral, imaging techniques should 
be performed to assess tumor location and size in order to aid in surgical planning. MRI 
is preferred for imaging masses of the extremities, head, trunk, and neck, while CT is 
useful for imaging abdominal, visceral, or retroperitoneal masses. A core needle biopsy 
or incisional biopsy of the tumor should also be performed for histological examination to 
aid in determination of STS subtype and grade. The less invasive method of a core 
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needle biopsy is preferred and has shown efficacy for accurately determining the 
subtype of STS in 88% of patients, whereas, incisional biopsy is often employed when 
more tumor tissue is needed for the use of molecular analysis, flow cytometry, or 
cytogenetics35. Furthermore, PET imaging, can distinguish benign tumors from 
sarcomas, having the greatest sensitivity for high grade tumors. Lastly, due to the 
propensity for STS lung metastasis, a chest CT scan is recommended after diagnosis of 
STS to discern whether pulmonary nodules are present. Similarly, patients with known 
angiosarcoma should undergo brain imaging due to this tumor’s propensity for 
metastatic spread to the central nervous system. 
 Tumor grade, which should only be applied to untreated primary STSs, is indicative 
of how likely a tumor is to grow and disseminate and thus it is an important factor when 
planning treatment regimens. The two most predominant systems for grading STSs are 
those proposed by the National Cancer Institute and the Fédération Nationale des 
Centres de Lutte Contre le Cancer (FNCLCC). The FNCLCC is more precisely defined 
and has revealed greater efficacy, therefore it is the preferred system. However, grading 
is not valuable for the prognosis of all STS subtypes.  Subtypes excluded from grading 
are MPNST, angiosarcoma, alveolar soft part sarcoma, extraskeletal myxoid 
chondrosarcoma, clear cell sarcoma, and epithelioid sarcoma.   Three prognostic factors 
are used for defining tumor grade according to FNCLCC: tumor differentiation, mitotic 








Table 1.2 FNCLCC Histological Grading System 
Histological Parameter Definition 
Tumor Differentiation  Score 1: Sarcomas closely resembling 
normal adult mesenchymal tissue and 
potentially difficult to distinguish from the 
counterpart benign tumor (e.g. well-
differentiated liposarcoma, well-differentiated 
leiomyosarcoma) 
 Score 2: Sarcomas for which histological 
typing is certain (e.g. myxoid liposarcoma, 
myxofibrosarcoma) 
 Score 3: Embryonal and undifferentiated 
sarcomas, synovial sarcomas, sarcomas of 
doubtful type 
Mitotic Count 
(1 HPF measures 0.1734 mm2) 
 Score 1: 0-9 mitoses per 10 HPF 
 Score 2: 10-19 mitoses per 10 HPF 
 Score 3: >19 mitoses per 10 HPF 
Tumor Necrosis  Score 0: No necrosis 
 Score 1: <50% tumor necrosis 
 Score 2: ≥50% tumor necrosis 
Histological Grade  Grade 1: total score 2, 3 
 Grade 2: total score 4, 5 
 Grade 3: total score 6, 7, 8 
 
While tumor grade is indicative of tumor aggressiveness, tumor stage determines the 
size of the primary tumor and the extent to which the tumor has already spread.  The 
staging system most commonly used for STS is the TNM system created by the 
International Union for Cancer and the American Joint Committee on Cancer (AJCC)36.  
The TNM staging system incorporates four factors: tumor size and depth (T), lymph 
node involvement (N), distant metastasis (M), and histologic grade (G) (Table 1.3).  
STSs of the extremities and trunk are staged with the TNM system; however, an 
alternate system should be used for STSs of the retroperitoneum as other factors 





Table 1.3 AJCC’s TNM Staging System 
Primary Tumor (T) TX Primary tumor cannot be assessed  




Tumor 5 cm or less in greatest dimension 
 Superficial tumor 




Tumor more than 5 cm in greatest dimension 
 Superficial tumor 
 Deep tumor 
Regional Lymph 
Nodes (N) 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
Distant Metastasis 
(M) 
M0 No distant metastasis 
M1 Distant metastasis 
Histologic Grade 
(G) 
GX Grade cannot be assessed 
G1 Grade 1 
G2 Grade 2 





T1a N0 M0 G1, GX 
T1b N0 M0 G1, GX 
Stage IB 
T2a N0 M0 G1, GX 
T2b N0 M0 G1, GX 
Stage IIA 
T1a N0 M0 G2, G3 
T1b N0 M0 G2, G3 
Stage IIB 
T2a N0 M0 G2 
T2b N0 M0 G2 
Stage III 
T2a, T2b N0 M0 G3 
Any T N1 M0 Any G 
Stage IV 









1.5 Treatment  
The goal of any treatment plan is to minimize tumor recurrence, while maintaining 
function and quality of life for the patient.  Due to STS heterogeneity, treatment plans 
vary based on subtype and extent of disease. According to the National Comprehensive 
Cancer Network (NCCN) guidelines, surgical resection is an essential component of 
treatment for primary low grade STS tumors of the extremities and trunk wall37.  Efforts 
to achieve a complete resection with negative margins of at least 1 cm should be made, 
but if tumor margins are close, the addition of adjuvant radiation therapy is 
recommended. When primary tumors are intermediate to high grade, greater than 5 cm 
in size, or deep, the addition of radiation therapy is also recommended.  For patients 
with high grade primary tumors, the NCCN recommends resection alone or along with 
the following: pre-operative radiation therapy, post-operative radiation therapy, 
neoadjuvant chemotherapy, or adjuvant chemotherapy. 
Radiation therapy (RT) dose is dependent upon tissue location and tolerance.  
Newer techniques, including intensity modulated RT, intraoperative RT, and 
brachytherapy have demonstrated improved outcomes in STS patients38–40. Intensity 
modulated RT is beneficial for its ability to reduce exposure of normal tissue surrounding 
the tumor to high dose radiation, whereas intraoperative RT is a process in which 
radiation treatment occurs during surgery. Brachytherapy is the use of radioactive seeds, 
which are implanted into the tumor bed through the use of catheters and can include 
low-dose rate, fractionated high-dose rate, or intraoperative high-dose rate therapy. 
Although the value of chemotherapy remains a subject of considerable debate, 
distinct STS histologies have shown chemosensitivity to certain regimens, thus, 
chemotherapy should be prescribed based upon STS subtype and location. The 
pediatric Ewing sarcomas and alveolar/embryonal rhabdomyosarcomas are routinely 
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treated with neoadjuvant chemotherapy (vincristine, cyclophosphamide, doxorubicin) 
due to their high risk for metastasis and sensitivity to chemotherapy.  Synovial sarcoma 
is another chemosensitive tumor, with progression-free survival (PFS) response rates for 
combination therapy of ifosfamide and doxorubicin showing 58% in one study41.  For 
patients with leiomyosarcoma, gemcitabine and docetaxel combination therapy has 
shown PFS rates of 16%42. Yondelis, a more recently developed synthetic 
chemotherapeutic drug originally derived from the marine tunicate ecteinascidia 
turbinata, has shown PFS rates of up to 51% in patients with liposarcoma and 
leiomyosarcoma43.   
Current treatment for patients with metastatic disease often comprises resection, 
radiation therapy, and/or chemotherapy.  First line chemotherapeutic treatments include 
ifosfamide (alkylating agent) and doxorubicin (anthracyclin antibiotic), which have proven 
the most active against metastatic soft tissue sarcomas, yet still maintain paltry response 
rates observed in only 15-35% of patients44,45. Single agent chemotherapy regimens that 
should be considered are doxorubicin, epirubicin, and ifosfamide, which have shown 
response rates in metastatic STS46,47.  Combination chemotherapy regimens consist of 
AIM (adriamycin, ifosfamide, and mesna); MAID (mesna, adriamycin, ifosfamide, and 
dacarbazine); gemcitabine with either docetaxel, vinorelbine, or dacarbazine; and 
doxorubicin along with dacarbazine. For many patients with metastatic soft tissue 
sarcoma, chemotherapy is used with palliative intent- to reduce tumor burden, slow 
disease progression, and improve symptoms.  While some studies have shown 
enhanced PFS, no studies have shown significant overall survival improvement and 
potential benefits may be offset by treatment-related toxicities, especially upon use of 
combination chemotherapy48–50.  Yet, molecular pathogenesis has provided key insight 
towards developing novel chemotherapeutic treatments.  For example, patients with ckit 
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positive gastrointestinal stromal tumors have shown 70% PFS rates for 12 months after 
treatment with Imatinib, a tyrosine kinase inhibitor known to inhibit ckit, depicting 
increased effectiveness of targeted therapies51. The effectiveness of targeted therapies 
in comparison to alkylating or intercalating agents reinstates the need to uncover specific 
molecular markers that can be utilized to develop more compelling chemotherapeutic 
agents.  Additionally, because STS chemotherapeutic agents exhibit varied PFS rates, it 
is a challenge for physicians to identify which patients will benefit from treatment, thus, 
markers to assess chemotherapeutic efficacy in patients with certain types of STS must 
be determined.  These prognostic markers may then identify which patients will benefit 
from potential chemotherapeutic regimens, while sparing those who will not benefit from 
possible toxicity-related treatment problems.   
 
1.6 Clinical Outcomes 
Multiple studies have shown that tumor size, stage, and histologic grade are 
important indicators of clinical outcome for patients with STS52–54. In one study of over 
1000 patients with STS of the extremities, it was found that being over the age of 50 and 
having positive resected margins predicted local recurrence, while tumor grade and size 
were the main predictors of distant recurrence and survival53. Other factors associated 
with survival include age, histologic subtype, and anatomic site55. 
 For STS patients who are successfully treated of their primary tumor, approximately 
25% will go on to develop  metastatic disease and once the primary tumor exceeds 5 cm 
in size, is deep to the fascia, and intermediate or high grade, the incidence of metastasis 
increases to 40-50%56,57.  Furthermore, approximately 10% of patients have detectable 
metastases at primary tumor diagnosis and the majority of patients with metastatic 
disease are incurable17. Thus, metastasis, via hematogenous dissemination, remains 
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one of the most lethal aspects of soft tissue sarcomas and constitutes the greatest 




Section 2: Tumor Microenvironment in Metastasis 
2.1 Tumor Microenvironment (TME)  
The TME is pivotal to cancer progression, as it establishes a permissive and 
supportive environment for the cancer cell.  It consists of extracellular matrix 
components (collagen, elastin, fibrilin, fibronectin, and proteoglycans), cellular 
components (immune cells, endothelial cells, adipocytes, fibroblasts), nerves, and 
vasculature all within close proximity to the malignant cancer cells. 
Dvorak first observed that the tumor microenvironment contains striking 
similarities to that of an active wound and, thus, described tumors as “wounds that do 
not heal”58. During the normal wounding process, quiescent fibroblasts undergo 
activation to become myofibroblasts, producing alpha-smooth muscle actin (α-SMA), an 
important component of the cytoskeleton involved in cell contractility and motility59.  
Additionally, these activated fibroblasts promote angiogenesis and secrete a complex 
extracellular matrix (ECM) to further assist in repairing the damaged tissue.  After 
completing reparation of the wound, activated fibroblasts undergo programmed cell 
death and are eliminated from the granulation tissue, whereas during tumor progression, 
fibroblasts in the TME are consistently present in the tumor stroma, remain perpetually 
activated, and are not removed by apoptosis60.   
 
2.2 Cancer-Associated Fibroblasts (CAFs) 
The most prominent cell type of the TME is the cancer-associated fibroblast 
(CAF)34. CAFs are mature, activated tissue fibroblasts associated with the solid tumor, 
which promote tumor progression by stimulating angiogenesis, cancer cell growth, 
invasion and metastasis, and through evasion of the immune response56.  They are 
activated by tumor cell secretion and stromal cell secretion of TGF-β1, which has been 
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shown to mediate α-SMA production, a marker of activated fibroblasts61. Through 
production of chemokines and growth factors such as fibroblast growth factor 2 (FGF-2), 
stromal-derived cell factor 1 (SDF-1), vascular endothelial growth factor (VEGF), 
hepatocyte growth factor (HGF), insulin-like growth factor (IGF), and epidermal growth 
factor (EGF), CAFs implement a direct effect upon promotion of growth in the 
surrounding epithelium and upon angiogenesis in the tumor stroma62. CAFs are also an 
important source of tumor inflammatory cytokines such as interleukin-1β (IL1-β)63. They 
participate in remodeling of the extracellular matrix by secretion of collagen type 1 and 
fibronectin, ECM proteins correlated with tumor stroma stiffening and enhanced 
metastatic potential64,65.  Tumor stroma stiffening, which is associated with more efficient 
TGF-β activation, may create a positive feedback loop through enhancing fibroblast 
activation and ECM synthesis, leading to increased matrix rigidity66,67.  CAFs are 
additionally a source for matrix-metalloproteinases (MMP)-2,-3, and -9, which degrade 
the ECM, potentiating tumor cell migration, invasion,  and metastasis, and creating a 
pathway for angiogenesis62.  Furthermore, CAFs secrete chemokines exploited by tumor 
cells to aid in their metastatic potential. During hypoxic conditions, tumor cells increase 
CXCR4 expression, enabling them to escape to a normoxic environment by migration 
towards SDF1/CXCL12-expressing CAFs; these SDF1/CXCL12-expressing CAFs 
additionally recruit endothelial-progenitor cells from the bone marrow that differentiate 
into tumor-associated vascular endothelial cells, which lay the foundation for angiogenic 
growth68,69.  CAFs have also been shown to be involved in chemotherapeutic resistance.  
With the secretion of ECM proteins, CAFs contribute to tumor ECM rigidity, causing 
increased interstitial fluid pressures, resulting in diminished chemotherapeutic delivery to 
the tumor64. Additionally, ECM rigidity has been associated with TGF-β1 tumorigenic 
functions, including EMT and cell motility70.  Other studies have shown that activated 
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fibroblasts are capable of preventing apoptosis of melanoma cells following cisplatin 
treatment71.  Factors secreted by CAFs, including HGF, have been implicated in 
promoting chemotherapeutic resistance by inhibiting drug induced apoptosis72. Studies 
clearly show the importance of CAFs in tumor advancement; however, their origin has 
not been conclusively determined. 
 
2.3 HSC-Derived Circulating Fibroblast Precursors 
Various origins for cancer-associated fibroblasts (CAFs) have been proposed, 
including resident tissue fibroblasts, smooth muscle cells, epithelial to mesenchymal 
transition, endothelial cells, and bone marrow-derived mesenchymal stromal cells 7–12.  
Yet, our studies, based upon a murine single hematopoietic stem cell transplantation 
model have demonstrated an additional, novel hematopoietic stem cell (HSC) source for 
CAFs and their precursors in the blood, circulating fibroblast precursors (CFPs)13.   
The HSC transplant method performed by our group is essential for the 
identification of HSC-derived cells in various murine disease models. In our transplant 
method, bone marrow is obtained from mice that ubiquitously express enhanced green 
fluorescent protein (EGFP) on a B6.SJL-Ptprcb Pep3b/BoyJ (C57BL/6-CD45.2) 
background.  The EGFP+ bone marrow then undergoes flow cytometric cell sorting 
using markers of HSCs (Lineage-, Sca-1+, ckithi, CD34-, side population), with Lineage- 
denoting cells that are negative for markers of B cells, T cells, granulocytes, and 
erythrocytes. Single cells are sorted into each well of a 96 well plate and undergo short 
term culture. Because the majority of HSCs remain in G0 for up to 3-4 days after 
initiation of cell culture, we select clones consisting of 20 or fewer cells after one week 
incubation (as clones consisting of greater than 20 cells are likely hematopoietic 
progenitor cells that do not remain quiescent for the initial 3-4 days in culture)73.  This 
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clonal population of putative HSCs recovered from the wells is then intravenously 
injected into a black syngeneic B6.SJL-Ptprca Pep3b/BoyJ (C57BL/6-CD45.1) mouse (in 
order to distinguish donor from recipient, which can be done by examining presence or 
absence of EGFP or CD45.1 expression) whose bone marrow has been ablated through 
lethal irradiation.  After 2 months, the mice are checked for multilineage engraftment. 
The defining property of a HSC is in its ability to repopulate the bone marrow and 
reconstitute hematopoiesis following transplantation, thus the presence of multilineage 
engraftment unequivocally indicates an HSC origin for any EGFP+ cell in our 
transplanted mice. 
Our group employed this HSC transplant method to reveal that EGFP+ cells 
derived from the bone marrow of clonally engrafted mice gave rise to fibroblasts in vitro 
and expressed procollagen 1-α1, discoidin domain receptor 2 (DDR2, receptor for 
collagen), vimentin, and fibronectin mRNA, all markers of fibroblasts74.  In murine 
melanoma and Lewis lung carcinoma tumor models, our group previously identified 
HSC-derived EGFP+ cells that incorporated into the tumor stroma and gave rise to cells 
phenotypically resembling fibroblasts in the tumor capsule13. Further analysis revealed 
these cells expressed type 1 procollagen and α-SMA, indicating that these HSC-derived 
cells in the tumor stroma were indeed fibroblasts, specifically activated fibroblasts13. Our 
group then went on to examine whether the circulating precursors to these fibroblasts 
homed to and were present within the tumor stroma. CFPs were found in vivo in the 
tumor stroma, most interestingly within the tumor blood vessels and it was determined 
that these CFPs were of HSC origin and could be defined as CD45+ DDR2+ cells 
expressing markers associated with the monocyte lineage14.   CFP number increased in 
correlation with tumor progression and CFPs were shown to migrate in response to 
tumor-conditioned media14. Additionally, CFPs were found to express chemokine 
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receptor type 2 (CCR2), a receptor for monocyte chemoattractant protein 1 (MCP-1), 
and it was further found that CFP migration was MCP-1 dependent14.  This research 
clearly revealed a HSC origin for murine CFPs and suggested their role in tumor 
progression; however, the identification of human HSC-derived CFPs had yet to be 
studied. 
To examine the origin of human CFPs, our group obtained peripheral blood from 
human subjects, then cultured and stained the cells for fibroblast markers.  It was found 
that peripheral blood mononuclear cells stained positive for αSMA, pro-collagen type 1, 
vimentin, and 5B5, all markers of fibroblasts15. A subsequent study was performed on 
peripheral blood obtained from three female subjects transplanted with GCSF-mobilized 
stem cells from male donors15. Non-adherent mononuclear cells derived from the 
peripheral blood of the female subjects were cultured and fluorescence in situ 
hybridization (FISH) analysis revealed the presence of both X and Y chromosomes in all 
cultured cells, indicating the donor origin of CFPs.  Although this study revealed the 
donor origin of human CFPs, further evidence was needed to unequivocally show an 
HSC origin for CFPs.  An additional study was performed on the peripheral blood of two 
untreated patients with Philadelphia chromosome positive chronic myelogenous 
leukemia (CML).  The Philadelphia chromosome occurs when chromosomes 9 and 22 
translocate, resulting in the fusion of the BCR and C-ABL genes.  FISH analysis for the 
BCR/ABL translocation on cultured non-adherent mononuclear cells revealed the 
presence of the BCR-ABL translocation.  Because CML is a clonal disorder of the HSC, 
the presence of the BCR-ABL translocation strongly indicates a HSC origin for human 






Chapter 2: Rationale, Hypothesis, and Specific Aims 
Rationale 
Our studies, based upon a murine single hematopoietic stem cell transplantation 
model have demonstrated that hematopoietic stem cells (HSCs) are a novel source for 
cancer-associated fibroblasts (CAFs) and their blood precursors, circulating fibroblast 
precursors (CFPs).  Our research has shown that murine CFPs (CD45+ DDR2+) are 
present in the peripheral blood and increase with tumor burden, implicating their 
importance in tumor progression. Our lab has also uncovered an HSC origin for human 
CFPs.  However, the identification and characterization of human CFPs in cancer, 
specifically soft tissue sarcoma, has yet to be established.   Preliminary evidence from 
our lab suggests we are capable of isolating CFPs from human peripheral blood and 
once cultured, CFPs exhibit markers of fibroblasts.  
Cancer-associated fibroblasts (CAFs), potentially derived from circulating 
fibroblast precursors (CFPs), are mature tissue fibroblasts associated with the solid 
tumor and have been shown to promote tumor progression by stimulating angiogenesis, 
cancer cell growth, invasion and metastasis, and through evasion of the immune 
response.  CAFs implement these effects by production of various growth factors (such 
as VEGF, a potent angiogenesis inducer), matrix metalloproteinases (such as MMP9 
which degrades collagen and fibronectin, allowing the tumor cell to transverse the 
basement membrane), and through production of chemokines and cytokines.  Our lab 
has shown that CFPs, a precursor to CAFs, increase with tumor burden, are present in 
the tumor stroma, and migrate in response to tumor conditioned media, suggesting that 
CFPs may play a direct role in promoting the progression and metastasis of solid 
tumors. Additionally, no studies have investigated the role of CAFs in soft tissue 
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sarcoma progression. We are therefore interested in uncovering whether CFP-derived 
fibroblasts play a functional role in soft tissue sarcoma metastasis through production of 
specific chemokine, cytokine, and growth factors involved in promoting the proliferation, 
migration, and invasion of sarcoma cells. 
 
Hypothesis 
HSC-derived CFPs are present in patients with soft tissue sarcoma and promote soft 
tissue sarcoma tumor cell proliferation, migration, and invasion in vitro. 
 
Specific Aims  
Aim 1: To isolate, characterize, and quantify circulating fibroblast precursors 
(CFPs) in patients with soft tissue sarcoma through analysis of hematopoietic and 
fibroblastic marker expression. Mononuclear cells were isolated via ultra-density 
centrifugation from peripheral blood and utilized immediately or cultured for growth of 
fibroblasts and examined for presence of hematopoietic and fibroblastic markers by 
immunofluorescence, flow cytometry, and quantitative real-time polymerase chain 
reaction. 
 
Aim 2: To determine the role of CFP-derived fibroblasts from patients with soft 
tissue sarcoma in promoting proliferation, migration, and invasion of sarcoma 
cells. The ability of CFP-derived fibroblasts to promote proliferation was assessed via 
Cyquant Direct Cell assay and ability to promote migration and invasion was assessed 
via transwell assays.  CFPs were tested for production of chemokine, cytokine, and 
growth factors associated with metastatic progression (i.e. ability to promote 






















Figure 1. Specific Aims. Aim 1: To isolate, characterize, and quantify circulating 
fibroblast precursors (CFPs) in patients with soft tissue sarcoma through analysis of 
hematopoietic and fibroblastic marker expression. Aim 2: To determine the role of CFP-
derived fibroblasts from patients with soft tissue sarcoma in promoting proliferation, 
migration, and invasion of sarcoma cells. 
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Chapter 3: Significance 
90% of all cancer deaths are due to metastatic disease, making it the single most 
significant challenge to management of patients with malignant neoplasms.  Patients 
with metastatic soft tissue sarcomas have a five year survival rate of 16% and only 15-
35% of patients respond to standard chemotherapeutic regimens44,45,75. Although many 
chemotherapeutic agents target the tumor cell, few agents target the tumor stroma even 
though it is an essential component of the tumor, providing a supportive and permissive 
habitat for tumor progression. Cancer-associated fibroblasts (CAFs) are the most 
abundant cell type of the tumor microenvironment and promote metastasis through 
production of factors that support tumor cell growth, vascularization, migration and 
invasion, escape from immune response, and chemotherapeutic drug resistance62.  
While multiple origins for CAFs have been proposed, our group has shown a 
hematopoietic stem cell (HSC)-derived circulating fibroblast precursor (CFP) origin for 
CAFs13.  This HSC-derived CFP origin for CAFs is especially pertinent in the realm of 
soft tissue sarcomas that have a predilection towards hematogenous dissemination.  
Studies have demonstrated the ability of bone marrow derived cells to colonize pre-
metastatic sites prior to tumor cell colonization, further implicating a role of HSC-derived 
cells from the bone marrow in metastatic progression65.  Our research will elucidate the 
effects of HSC-derived CFPs on soft tissue sarcoma metastasis, potentially identifying 
novel factors responsible for disease progression.  Furthermore, once CFPs are 
implicated in soft tissue sarcoma metastasis, they may serve as unique therapeutic 
targets.  Additionally, the known HSC-origin of CFPs may allow us to target CFPs at an 
even earlier state, depleting all possible HSC-derived CFPs that have the potential to 
differentiate into CAFs within the tumor microenvironment. 
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Conclusively, the key to uncovering new therapies for treating advanced cancers, 
such as metastatic soft tissue sarcoma, lies in the enhanced understanding of their 
metastatic environment. Our studies will result in a better understanding of human tumor 
metastasis, specifically through CFP marker expression profiling and discovery of the 
role of CFPs in promoting sarcoma tumor cell proliferation, migration, and invasion.  Our 
studies may then lead to the identification of unique CFP-based therapies for soft tissue 





















Chapter 4: Specific Aim 1 
To isolate, characterize, and quantify CFPs in patients with soft tissue sarcoma through 
analysis of hematopoietic and fibroblastic marker expression. 
 
Section 1: Introduction 
Previous studies in our lab, based upon a murine single hematopoietic stem cell 
transplantation model have demonstrated that hematopoietic stem cells (HSCs) are a 
novel source for cancer-associated fibroblasts (CAFs) and their blood precursors, 
circulating fibroblast precursors (CFPs)13.  Our lab’s research has shown that murine 
CFPs (CD45+ DDR2+) are present in the peripheral blood and increase with tumor 
burden14. Our lab has also uncovered a HSC origin for human CFPs15.  However, the 
identification and characterization of human CFPs in cancer, specifically soft tissue 
sarcoma, has yet to be established.  CFP classification is based upon expression of 
markers that recognize both their hematopoietic origins and fibroblastic traits, thus we 
define CFPs as peripheral blood cells expressing the hematopoietic cell marker CD45 
(common leukocyte antigen) along with the fibroblast marker, discoidin domain receptor 
2 (DDR2, collagen receptor).  Collagen type I, another marker of fibroblasts was also 
examined. Because CFPs have the potential to differentiate into activated CAFs in the 
tumor microenvironment, further examination of markers of activated fibroblasts was 
conducted; these included vimentin and alpha-smooth muscle actin (α-SMA).   
 
Section 2: Hypothesis 
We hypothesized that CFPs were present in the peripheral blood of patients with soft 




Section 3: Materials and Methods 
Cell Culture of Human Peripheral Blood  
Peripheral blood (9-15 mL) was drawn from patients with soft tissue sarcoma and 
from control subjects (All Cells #WB001-NH) without any known malignancies and 
collected in sodium heparin-coated vacutainer tubes (BD #367878). Mononuclear cells 
were isolated via density centrifugation with Lympholyte H (Cedarlane #CL5010) and 
either frozen for later analysis or plated on a T25 tissue culture treated flask (Corning 
#430639) and incubated at 37°C in free gas exchange at 5% CO2.  After a 20 hour 
incubation period, non-adherent HSC-derived mononuclear cells were removed and 
plated on 4-well fibronectin-coated tissue culture plates (Corning #354559) for 14-21 
days at a concentration of 6x105 cells per well in 1 mL of Minimum Essential Medium α 
(MEMα) (Life Technologies #12561) supplemented with 20% fetal bovine serum (Atlanta 
Biologicals, lot #6005C) and penicillin streptomycin in order to promote the differentiation 
of CFPs into fibroblasts (CFP-derived fibroblasts). The rationale for obtaining the non-
adherent population of mononuclear cells is derived from the concept that two types of 
stem cells are present in the bone marrow- hematopoietic stem cells (HSCs) and 
mesenchymal stem/stromal cells (MSCs).  MSCs are characterized by their ability to 
adhere to plastic, thus, we obtain the non-adherent population in order to enrich for 
HSC-derived cells76. 
 
 Cell Culture of HT-1080 and HFF-1 cells 
The human HT-1080 fibrosarcoma and HFF-1 foreskin fibroblast cell lines were 
purchased from American Type Culture Collection (ATCC). HT-1080 cells (ATCC #CCL-
121) were cultured in Eagle’s Minimum Essential Medium (ATCC #30-2003) 
supplemented with 10% Fetal Bovine Serum (ATCC #30-2020) and HFF-1 cells (ATCC 
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#SCRC-1041) were cultured in Dulbecco’s Modified Eagle’s Medium (ATCC #30-2002) 
supplemented with 15% Fetal Bovine Serum (ATCC #30-2020). Both cell lines were 
incubated at 37°C in free gas exchange at 5% CO2 and allowed to grow to confluency 
before splitting. Cell lines were used below passage 8. 
 
Immunofluorescence Staining 
 Antibodies were first titrated and tested on cultured HFF-1 fibroblast cells in order 
to optimize our staining methods for fibroblast markers (Figure 2). 
After 14-21 days culture, CFP-derived fibroblasts were washed in phosphate 
buffered saline (PBS), then fixed with 4% paraformaldehyde and stored in 0.05% sodium 
azide until ready for staining. Cells were then washed 3 times with PBS. 0.02% Triton X 
was added for 20 minutes, then cells were again washed 3 times with PBS.  Cells were 
then blocked for 1 hour in 5% donkey serum in 3% bovine serum albumin/PBS. Primary 
antibodies for alpha smooth muscle actin (αSMA), Collagen 1, and Vimentin (Table 4.1) 
were added and incubated overnight at 4°C. Cells were washed 3 times with PBS and 
secondary antibodies for Cyanine 3 (Cy3) and Fluorescin Isothiocyanate (FITC)  
(Table 4.1) were added for 1 hour, incubated at room temperature and protected from 
light. Cells were washed 3 times with PBS, then Hoechst 33342 (Invitrogen #H3570) 
diluted 1:25000 in PBS was added for 8 minutes. Fluorogel (Electron Microscopy 
Sciences #17985-10) was then added before slides were coverslipped. Slides stained 
with Secondary only were used as controls for non-specific antibody staining. 
Epifluorescence and differential contrast (DIC) microscopy was conducted using a Nikon 
Eclipse 90i microscope with NIS Elements AR3.2 Software. Images were processed 
















Figure 2. Immunohistochemical standardization of staining for fibroblast markers. 
Optimization of antibody staining for activated fibroblast markers, including αSMA  
(red; A-D), Col I (red; E-H), and Vimentin (green; M-P), with cultured human foreskin 
fibroblast (HFF-1) cells. Nuclei were stained with Hoechst dye (blue). Secondary only 
control staining for αSMA/Col I (I-L) and Vimentin (Q-T). Mag bars in A-T = 25 µm. 
 
Table 4.1 Antibodies Used for Immunofluorescence Staining 
Antibody Company Catalog # Lot # Concentration 
Rabbit αSMA Abcam ab15734 GR110540-1 1:50 in PBS 
Mouse Collagen 1 Abcam ab90395 GR117081-1 1:50 in PBS 
Rabbit Collagen 1 Abcam ab34710 GR33585-2 1:50 in PBS 
Mouse Vimentin Abcam ab8979 GR39704 1:50 in PBS 
Donkey anti Rabbit-Cy3 Jackson 715-165-152 109623 1:100 in PBS 
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Flow Cytometry Staining 
Antibodies were first titrated to determine optimal staining concentrations for flow 
cytometric analysis. 
After mononuclear cells were isolated from peripheral blood via density 
centrifugation with Lympholyte H (Cedarlane #CL5010), they were washed, then 
resuspended in cell culture freeze media with DMSO (Millipore #S002-5F), stored at  
-80°C overnight, then placed in liquid Nitrogen storage until analysis. When ready for 
analysis, cells were quickly thawed in a 37°C water bath, washed, then resuspended in 
growth media and allowed to recover for 1 hour in an incubator at 37°C in free gas 
exchange at 5% CO2.  Cells were then counted with Trypan Blue for viability, washed, 
and allocated into tubes for staining. Cells were resuspended in 100 μL phosphate 
buffered saline (PBS), then 11 μL Human AB Serum (10% of cell suspension volume) 
was added to block non-specific antibody binding. After 1 minute incubation, cells were 
stained with CD45 and Discoidin Domain Receptor 2 (DDR2) antibodies (Table 4.2) and 
incubated for 20 minutes on ice, protected from light.  After washing, APC secondary 
antibody was added and cells were incubated for 20 minutes on ice, protected from light. 
Live/Dead Fixable Cell Stain (Invitrogen #L-23102) was used according to 
manufacturer’s protocol. Cells were acquired on BD LSR Fortessa Analytic Flow 
Cytometer. Positive staining and gating strategy were determined by comparison to 








Table 4.2 Antibodies Used for Flow Cytometry 
Antibody Company Catalog # Lot # Clone # 




563204 3172808 H130 
Mouse IgG2B DDR2 R&D Systems MAB25381 CACM0112051 290804 
Rat anti Mouse 
IgG2B APC 
R&D Systems F0133 ACKM0113121 332723 
 
Quantitative Real-time PCR 
Total RNA from cells was isolated using Trizol reagent (Life Technologies 
#15596) in combination with the RNeasy Mini Kit (Qiagen #74104). 0.5 µg total RNA was 
reverse transcribed in a 20 µL reaction using the iScript cDNA synthesis kit (Bio-Rad 
#170-8890). Quantitative Real-time PCR was performed with 2.5 µL of a 1:20 dilution of 
reverse-transcribed cDNA, along with SsoAdvanced Universal Probes Supermix (Bio-
Rad #172-5284) and primer-probe combinations (Table 4.3) designed through the 
Universal ProbeLibrary Design Center (Roche) in a 10 µL reaction in the Light Cycler 96 
(Roche). Cycling conditions were conducted according to the manufacturer’s protocol.  
Reactions were run in triplicate for each cDNA sample, along with non-reverse 
transcriptase and negative controls. Relative gene expression was quantified based on 
Cq value measured against standard curves for each primer-probe set. Data were 
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 Peripheral blood was obtained after informed consent was given and subjects 
were enrolled into our Institutional Review Board approved study (CTO 101576) through 
the MUSC Hollings Cancer Center. All subjects consented were over 18 years of age 
and had soft tissue sarcoma, either metastatic or non-metastatic. 
 
Statistical Data Analysis 
 Data are presented as mean ± standard deviation of the value. To compare 
variables between 2 groups, the two-tailed unpaired Student t-test was performed in 




Section 4: Results 
Enrichment of HSC-derived cells from Human Peripheral Blood 
Bone marrow contains two types of stem cells: the hematopoietic stem cell 
(HSC) and the mesenchymal stem/stromal cell (MSC).  Previous dogma held that HSCs 
gave rise exclusively to blood lineage cells, while MSCs were capable of giving rise to 
mesenchymal cell types including adipocytes, endothelial cells, chondrocytes, 
osteoblasts/osteocytes, fibroblasts, and microglial cells77–83. Our lab has shown that 
HSCs are also capable of giving rise to mesenchymal cells- adipocytes, 
osteochondrogenic cells, fibroblasts/myofibroblasts, and microglial and perivascular cells 
of the brain74,84–87. Therefore, we are particularly interested in the plasticity and potential 
of HSC-derived cells.  Thus, it is imperative for our studies to examine populations 
enriched for HSC-derived cells in order to diminish MSC contamination and its 
corresponding effects.  As one of the characteristics of a MSC is adherence to plastic, 
we obtained the non-adherent population of cells from peripheral blood and cultured 
these for our studies in order to enrich for an HSC-derived population76.  To determine 
whether our non-adherence culture method was optimal towards enriching for cells of an 
HSC origin in the peripheral blood, flow cytometric analysis of expression of CD45 
(common leukocyte antigen), a known marker of hematopoietic cells, was performed.  
Peripheral blood was obtained from normal control subjects, then mononuclear 
cells (MNCs) were isolated via density centrifugation.  MNCs were saved for flow 
cytometric analysis or plated on a T25 tissue culture treated flask and incubated at 37°C 
in free gas exchange at 5% CO2.  After either a 2 hour or 20 hour incubation period, the 
non-adherent MNCs were removed from culture for flow cytometric analysis. As shown 
in Figure 3, obtaining the non-adherent population of MNCs is sufficient for enriching for 
CD45+ HSC-derived cells and this enrichment increases with increasing culture time 
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from 2 hrs to 20 hrs. Thus, by isolating and culturing the non-adherent population of 
peripheral blood MNCs, we selected for an enriched population of HSC-derived cells to 
be used in our studies. 



















Figure 3. Enrichment of hematopoietic-derived cells from the NAd population of 
MNCs. (A) Total peripheral blood (PB) mononuclear cells (MNCs) compared to the non-
adherent (NAd) population of MNCs derived after culture for either 2 hours (2 hr NAd) or 
20 hours (20 hr NAd) from two different normal control subjects (Norm 1 PB and Norm 2 
PB) were stained for CD45, the common leukocyte antigen, and analyzed via flow 
cytometry. CD45 FMO was used as a control for gating strategy. (B) Graphical depiction 




























































Characterization of Cultured CFPs from Human Peripheral Blood 
 In order to determine if our isolation and culture methods were sufficient for 
obtaining fibroblasts from human peripheral blood (CFP-derived fibroblasts), we cultured 
the non-adherent population of MNCs, shown to be enriched for hematopoietic-derived 
cells, from normal control subjects (n=3) for 14-21 days then performed 
immunohistochemical analysis for the following fibroblast markers: collagen I (Col I), 
vimentin, and alpha smooth muscle actin (αSMA) (Representative data shown in Figure 
4A).  Because there is no single specific fibroblast marker, we chose a panel of 
fibroblast markers to examine whether our cultured cells were indeed displaying a 
fibroblastic phenotype. We then performed the same immunohistochemical analysis on 
patients with metastatic STS (n=3) in order to determine whether CFP-derived 
fibroblasts were also present in the peripheral blood of patients with STS tumor burden 
(Representative data shown in Figure 4B). Our data demonstrate the presence and 
feasibility of isolating CFPs from human peripheral blood, in both normal controls and 
patients with STS, and show that once cultured, CFPs were positive for Col I, Vimentin, 











Figure 4. Immunohistochemical analysis of cultured CFPs. (A) Representative 
image of CFPs cultured from the peripheral blood of a normal control subject. Cells were 
stained with antibodies for Col I (red; B), Vimentin (green; C,H), and αSMA (red; G). 
Nuclei were stained with Hoechst dye (blue). Merged images for Col I and Vimentin 
(D,E) and αSMA and Vimentin (I,J). Secondary only control staining for Col I/ αSMA (L) 
and Vimentin (M).    (B) Representative image of CFPs cultured from the peripheral 
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blood of a patient with metastatic STS (leiomyosarcoma). Cells were stained with 
antibodies for Col I (red; B), Vimentin (green; C,G), and αSMA (red; F). Nuclei were 
stained with Hoechst dye (blue). Merged images for Col I and Vimentin (D) and αSMA 
and Vimentin (H). Secondary only control staining for Col I/ αSMA (J) and Vimentin (K).  






















After confirming our ability to isolate and culture CFP-derived fibroblasts from the 
peripheral blood of normal control subjects and patients with STS, we aimed to further 
characterize these cultured CFPs through examination of mRNA expression levels for 
genes associated with a fibroblast-like phenotype via RT-qPCR (Figure 5).  Our data 
indicate that we indeed isolated CFPs from both STS patients and control subjects, as 
they revealed mRNA expression of the following hematopoietic and fibroblastic markers: 
CD45, DDR2, Col1, Vimentin, and αSMA. Our data further indicated differences between 
STS patients and control subjects as CD45, Collagen I (Col1), and Vimentin expression 
was decreased, while DDR2 expression was increased in CFPs from patients with STS 
as compared to CFPs from normal control subjects.  No significant difference in αSMA 
expression was found between the two cohorts.   
 
 
Figure 5. RT-qPCR characterization of CFPs from patients with STS 
RT-qPCR of mRNA expression levels in cultured CFPs from patients with STS (Pt CFP) 
and normal control subjects (Norm CFP) normalized to HPRT.  Each bar represents 
averaged expression for each group with n=4. *P<0.05 compared to Norm CFP. 
* 
* * * 
37 
 
Quantification of CFPs in Peripheral Blood of Normal Control Subjects and STS Patients 
 We then sought to determine whether CFP numbers varied in the circulation of 
patients with STS compared to normal control subjects without known malignancies. 
Peripheral blood MNCs were isolated (without culture), then stained with antibodies for 
CD45 (common leukocyte antigen) and discoidin domain receptor 2 (DDR2, a receptor 
for collagen) and analyzed via flow cytometry (Figure 6).   We define our CFPs as 
CD45+ DDR2+, as these two markers indicate both the hematopoietic origin and 
fibroblastic phenotype of our cell population. Flow cytometric analysis of five normal 
control subjects without known malignancies was compared to four STS patients, three 
of whom had metastatic disease (Table 4.4).  Flow cytometric analysis revealed no 
significant difference in the average percentage of CFPs present within the peripheral 
blood of patients with STS (mean ± standard deviation: 0.54 ± 0.20) compared to normal 
control subjects (mean ± standard deviation: 0.45 ± 0.51).  However, when examining 
individual data points it is apparent that patient 1, who had metastatic STS without 
treatment, had the highest percentage of CD45+ DDR2+ CFPs with a 2.3 fold increase 
compared to average normal control. Patient 1 showed an increased percentage of 
CFPs over two other patients (patient 3, 4) who also had metastatic STS, but were 
undergoing chemotherapeutic treatment (with Yondelis).  It was also noted that the 
patient without evidence of metastatic disease (patient 2) had a lower percentage of 
CFPs than either of the patients with metastasis or normal controls.  
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A.       B.       
Sample % CD45+ DDR2+ 
Norm 1 0.58 
Norm 2 0.23 
Norm 3 0.65 
Norm 4 0.76 
Norm 5 0.49 
Pt 1 1.21 
Pt 2 0.096 
Pt 3 0.31 
Pt 4 0.20 
 
 
Figure 6. CFP quantification in human peripheral blood. Peripheral blood (PB) 
mononuclear cells (MNCs) were isolated from normal control subjects (Norm MNCs) and 
patients with Soft Tissue Sarcoma (Pt MNCs) and stained with antibodies for CD45 and 
DDR2.  The percentage of CD45+ DDR2+ cells (CFPs) was analyzed via flow cytometry. 
(A) Summary of flow cytometric data is shown as % CD45+ DDR2+. (B) % CFPs shown 




Table 4.4 Patient Profiles for Figure 6 
Patient  Age Diagnosis Current Treatment 
1 61 Metastatic Synovial 
Sarcoma 
None 
2 66 Pleiomorphic 
Undifferentiated 
Sarcoma without 
evidence of metastases 
None 
3 72 Metastatic 
Angiosarcoma 
Yondelis 






Section 5: Discussion 
Our lab previously demonstrated that HSCs are a novel source for CAFs and 
their blood precursors, CFPs, and that murine CFPs (CD45+ DDR2+) were present in the 
peripheral blood and increased with tumor burden13,14. However, the identification and 
characterization of human CFPs in cancer, specifically soft tissue sarcoma, had not 
been established. Thus, the goal of this study was to isolate, characterize, and quantify 
CFPs in patients with STS. Our data revealed that our isolation technique for obtaining 
the non-adherent population of MNCs was sufficient for enriching for CD45+ HSC-
derived cells and that this enrichment was enhanced with increasing culture time (from 2 
hrs to 20 hrs). Immunohistochemical analysis of the cultured non-adherent MNC 
population from the peripheral blood of patients with metastatic STS and normal control 
subjects revealed CFPs were present in this fraction of human peripheral blood as these 
cultured cells displayed fibroblastic marker expression for collagen 1 (Col I), alpha 
smooth muscle actin (αSMA), and vimentin. Fibroblasts are known to secrete Col I, an 
important protein found in the extracellular matrix (ECM) and to express vimentin, a 
member of the intermediate filament family. αSMA is implicated in cell contractility and 
motility and fibroblast expression of αSMA has been associated with a myofibroblast or 
activated phenotype and is upregulated by TGF-β, particularly in the tumor 
environment88,89.  
RT-qPCR data revealed differences between STS patients and normal control 
subjects in mRNA expression of hematopoietic and fibroblastic markers. The decrease 
in CD45 expression in CFPs from patients with STS as compared to normal control 
subjects is of interest as studies have shown that CD45 is downregulated as fibrocytes 
(a cell type similar to that of CFPs) differentiate90,91. This may indicate that CFPs from 
patients with STS are further differentiated compared to CFPs from normal control 
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subjects. The increase in DDR2 expression in patients with STS compared to control 
subjects is also of interest as studies have shown that fibroblast spreading and migration 
is dependent upon DDR2 92–94. Additionally the decrease in Col1 expression, a ligand for 
DDR2, may cause DDR2 on the CFPs to not be saturated with collagen via autocrine 
signaling, potentially freeing DDR2 to bind to collagen at sites further away (such as the 
lung- a common site of STS metastasis), aiding in CFP migration. Thus, our RT-qPCR 
data may suggest that CFPs from patients with STS display a more differentiated and 
migratory phenotype compared to normal control subjects. 
Flow cytometric analysis of CD45+ DDR2+ cells revealed no significant difference in 
the average percentage of CFPs present within the peripheral blood of patients with STS 
compared to normal control subjects.  However, it was found that patient 1 who had 
metastatic STS without treatment showed the highest percentage of CD45+ DDR2+ 
CFPs than any of the subjects, with a 2.3 fold increase compared to average normal 
control.  Patients with metastatic STS were shown to have a higher percentage of CFPs 
compared to a patient with non-metastatic STS (patient 2). Patient 2, without evidence of 
metastatic disease, showed a lower percentage of CFPs than patients with metastatic 
disease and even that of normal control subjects. Given that this was the only non-
metastatic patient in this data set, it remains to be determined if this CFP profile would 
hold for other patients without evidence of metastatic disease.  If so, it may indicate that 
CFPs are a unique marker for the metastatic phase of disease.   Of further interest is 
that patient 1 showed an increased percentage of CFPs over two other patients (patient 
3, 4) who also had metastatic STS, but were undergoing chemotherapeutic treatment.  
This may suggest chemotherapeutic treatment functions in part by suppressing the CFP 
population, reinforcing the idea of an important role for CFPs in metastatic disease. This 
data may also implicate percentage of CFPs as a biomarker for response to 
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chemotherapeutic treatment in metastatic disease. Given the small number of samples, 
further analysis of patients with metastatic STS receiving chemotherapeutic treatment 
should be compared to patients without treatment in order to determine if this trend is 
applicable to the majority of STS patients and whether this trend is associated with 
certain STS subtypes. This knowledge would be especially efficacious in the treatment 
of patients with STS because chemotherapeutic agents have exhibited varied response 







Chapter 5: Specific Aim 2 
To determine the role of CFP-derived fibroblasts from patients with soft tissue sarcoma 
in promoting proliferation, migration, and invasion of sarcoma cells. 
 
Section 1: Introduction 
Cancer-associated fibroblasts (CAFs), some of which are potentially derived from 
circulating fibroblast precursors (CFPs), are mature tissue fibroblasts associated with the 
solid tumor and have been shown to promote tumor progression by stimulating 
angiogenesis, cancer cell growth, invasion and metastasis, and through evasion of the 
immune response.  CAFs implement these effects by production of various growth 
factors (such as VEGF, a potent angiogenesis inducer), matrix metalloproteinases (such 
as MMP9 which degrades collagen and fibronectin, allowing the tumor cell to transverse 
the basement membrane), and through production of chemokines and cytokines.  Our 
lab has shown that CFPs, a precursor to CAFs, contribute to tumor growth and migrate 
in response to monocyte chemoattractant protein-1 (MCP-1), suggesting that CFPs may 
play a direct role in promoting the progression and metastasis of solid tumors.  We, 
therefore, aimed to test the hypothesis that CFP-derived fibroblasts play a functional role 
in soft tissue sarcoma metastasis through production of specific chemokine, cytokine, 
and growth factors involved in promoting the proliferation, migration, and invasion of 
sarcoma cells. 
 
Section 2: Hypothesis 
We hypothesized that CFP-derived fibroblasts, through production of specific 
chemokine, cytokine, and growth factors promoted proliferation, migration, and invasion 
of sarcoma cells. 
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Section 3: Materials and Methods 
Cell Culture of Human Peripheral Blood  
Peripheral blood (9-15 mL) was drawn from patients with soft tissue sarcoma and 
from control subjects (All Cells #WB001-NH) without any known malignancies and 
collected in sodium heparin-coated vacutainer tubes (BD #367878). Mononuclear cells 
were isolated via density centrifugation with Lympholyte H (Cedarlane #CL5010) and 
plated on a T25 tissue culture treated flask (Corning #430639) and incubated at 37°C in 
free gas exchange at 5% CO2.  After a 20 hour incubation period, non-adherent HSC-
derived mononuclear cells were removed and plated on 4-well fibronectin-coated tissue 
culture plates (Corning #354559) for 14-21 days at a concentration of 6x105 cells per 
well in 1 mL of Minimum Essential Medium α (MEMα) (Life Technologies #12561) 
supplemented with 20% fetal bovine serum (Atlanta Biologicals, lot #6005C) and 
penicillin streptomycin in order to promote the differentiation of CFPs into fibroblasts 
(CFP-derived fibroblasts).  Cells were then gently washed 3 times in MEMα and serum 
starved for 24 hours in 0.5 mL MEMα per well (6x105cells/ well). CM was collected and 
filtered to remove debris, then used for proliferation, migration, and invasion experiments 
(Figure 7). 
 
In vitro Generation of Tumor-Exposed CFPs 
HT-1080 Conditioned Media (CM)  was obtained by culturing 3x106 HT-1080 
cells in a T75 tissue culture plate (Corning #353136), then cells were gently washed 3 
times in MEMα to remove residual growth media, and cells were serum starved in 10 mL 
MEMα (Life Technologies #12561) for 24 hours. After 24 hours, HT-1080 CM was 
collected and filtered to remove debris.  
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 Peripheral blood was obtained from control subjects (All Cells #WB001-NH) 
without any known malignancies and collected in sodium heparin-coated tubes. 
Mononuclear cells were isolated via density centrifugation with Lympholyte H (Cedarlane 
#CL5010) and plated on a T25 tissue culture treated flask (Corning #430639) and 
incubated at 37°C in free gas exchange at 5% CO2.  After a 20 hour incubation period, 
non-adherent HSC-derived mononuclear cells were removed and plated on 4-well 
fibronectin-coated tissue culture plates (Corning #354559) at a concentration of 6x105 
cells per well in 1 mL of either MEMα (Life Technologies #12561) supplemented with 
20% fetal bovine serum (Atlanta Biologicals, lot #6005C) and penicillin streptomycin 
(Normal Control) or HT-1080 CM supplemented with 20% fetal bovine serum (Atlanta 
Biologicals, lot #6005C) and penicillin streptomycin (Tumor-Exposed) and cultured for 
growth of CFP-derived fibroblasts. Normal Control and Tumor-Exposed CFP-derived 
fibroblasts were cultured in their designated media for up to 15 days with media renewal 
every 3 days after the first week of culture. Normal Control and Tumor-Exposed cells 
were then gently washed 3 times in MEMα and serum starved for 24 hours in 0.5 mL 
MEMα per well (6x105 cells/well). CM was then collected and filtered to remove debris, 
then used for proliferation, invasion, and cytokine array experiments as an in vitro model 
of Tumor-Exposed CFPs (Figure 8, 9). 
 
Proliferation Assay 
 1x103 HT-1080 (human fibrosarcoma) cells were plated in triplicate in 150 µL of 
CM in individual wells of a 96-well tissue culture treated plate (Corning #3799). 
Proliferation was measured using CyQuant Direct Cell Proliferation Assay (Invitrogen 
#C35011) according to manufacturer’s protocol.  Fluorescence was read at 480nm 
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excitation and 535nm emission on a BioTek Synergy HT microplate reader using Gen 5 
software. 
 
Migration and Invasion Assay 
Prior to migration assay, inserts (Costar #3422 transwell permeable support 
8.0µm polycarbonate membrane) were coated with fibronectin (5 µg/mL) and incubated 
1 hour at 37°C, then air dried. 600 µL of conditioned media was placed in the bottom of 
individual wells (with 3 replicate wells) of a 24-well non-tissue culture treated plate 
(Corning #351147), then 1.5×104 HT-1080 (human fibrosarcoma) cells in 100 µL αMEM 
were placed in each insert.  
Prior to invasion assay, invasion chambers (BD #354480 BioCoat BD 
Matrigel Invasion Chamber, 8.0 µm PET Membrane) were allowed to come to room 
temperature. Then inserts were rehydrated for 2 hours at 37°C in warm DMEM. After 
rehydration, 750 µL of conditioned media was placed in bottom of individual wells (with 
each sample plated in triplicate wells) of a 24-well non-tissue culture treated plate 
(Corning #351147), then 5.0×104 HT-1080 cells in 500 µL αMEM was placed in each 
insert. 
After 8 hours (migration) or 22 hours (invasion) incubation at 37°C in free gas 
exchange at 5% CO2, inserts were removed and the top of each insert was gently 
scrubbed with a q-tip to remove cells that have not invaded through the membrane. 
Inserts were then stained with the Diff-Quik stain set (Siemens #B4132-1A).  10 high 
powered fields were counted on each insert using a Nikon Eclipse Ti-U microscope with 






Levels of cytokines in CM were measured with the Human XL Cytokine Array Kit 
(R&D Systems #ARY022) according to manufacturer’s protocol with the use of 500 µL 
CM in 1 mL Array Buffer 6 for each membrane. Membranes were then exposed to 
autoradiography film (MidSci #EBNU2) and average pixel density for each cytokine was 
analyzed using ImageJ software (NIH). 
 
Human Consent 
 Peripheral blood was obtained after informed consent was given and subjects 
were enrolled into our Institutional Review Board approved study (CTO 101576) through 
the MUSC Hollings Cancer Center. All subjects consented were over 18 years of age 
and had soft tissue sarcoma, either metastatic or non-metastatic. 
 
Statistical Data Analysis 
 Data are presented as mean ± standard deviation of the value. To compare 
variables between 2 groups, the two-tailed unpaired Student t-test was performed, with 




Section 4: Results 
CFP-derived fibroblasts from patients with STS promote HT-1080 fibrosarcoma 
proliferation, migration, and invasion 
 HSC-derived CFPs are a potential source for CAFs, which are known to promote 
tumor cell proliferation, migration, and invasion, all essential elements of metastatic 
progression95–97.  Although CAFs have not been investigated in STS progression or 
metastasis, given our identification of CFPs in patients with STS, we sought to 
investigate the functionality of these cells, particularly in relation to their ability to support 
tumor advancement.  In order to examine whether CFP-derived fibroblasts from patients 
with STS promote tumor cell progression, conditioned media (CM) was collected from 
cultured CFP-derived fibroblasts from either patients with STS or normal control subjects 
and assays were performed to analyze the ability of conditioned media from CFP-
derived fibroblasts to promote HT-1080 (human fibrosarcoma) cell proliferation, 
migration, and invasion.  Due to the rarity and heterogeneity of STS, our studies were 
performed on CFP-derived fibroblasts from patients with various types of STS.  As there 
are not cell lines for most types of STS, we utilized the HT-1080 cell line from ATCC as a 
standard cell line in each of our assays. Diagnosis and treatment status of patients is 
found in Table 5.1. 
One of the hallmarks of cancer progression is the ability of a tumor cell to sustain 
proliferation97.  Tumor cells continually proliferate through production of growth factor 
ligands, resulting in autocrine stimulation or through secretion of factors to normal cells 
in the surrounding environment, which may then respond to the tumor by supplying it 
with  growth factors95. Our studies found that CFPs from patients with STS were capable 
of promoting HT-1080 tumor cell proliferation over αMEM (Figure 7A). CFPs from one 
patient in particular, patient 8, who had metastatic myxoid liposarcoma, significantly 
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enhanced HT-1080 tumor cell proliferation over normal control subjects during all 3 time 
points. CFPs from patient 15 and 16, who also had metastatic myxoid liposarcoma 
showed significant increases in HT-1080 proliferation after 72 hours, potentially 
suggesting CFPs from patients with the myxoid liposarcoma subtype of STS have 
enhanced ability to promote sarcoma tumor cell proliferation. 
Another hallmark of tumor progression is the activation of invasion and 
metastasis97. This requires chemotactic migration of tumor cells, along with the ability of 
the tumor cell to protrude its cell membrane while remodeling and degrading the 
extracellular matrix (ECM)98.  During invasion, matrix degrading proteases, either 
produced by the tumor cell or recruited inflammatory cells present in the tumor 
microenvironment, produce MMPs that play an important role in tumor escape97. In order 
to examine whether CFPs were capable of enhancing sarcoma migration and invasion, 
transwell assays were performed using CFP conditioned media (CM) as a 
chemoattractant.  Our data indicate that CFPs from two of the three patients with STS 
promoted HT-1080 tumor cell migration over normal control (Figure 7B). Furthermore, 
CM from CFPs from all patients with STS showed increased HT-1080 invasion over 
αMEM. We found enhanced HT-1080 invasion toward CFP CM in 4 out of 9 patients with 
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Figure 7. CFPs from patients with STS promote HT-1080 sarcoma cell 
proliferation, migration, and invasion. Conditioned media (CM) from cultured CFP-
derived fibroblasts from patients (Pt) with STS (individual results) and normal (Norm) 
control subjects (averaged, n=4) was examined in vitro for ability to promote HT-1080 
fibrosarcoma proliferation after 24, 48 and 72 hours (A), ability to promote HT-1080 
migration (B)  through 0.8µm pore fibronectin coated transwells and invasion (C) through 













proliferation assay, fold change over αMEM is presented. * P<0.05 compared to normal 




Table 5.1 Patient Profiles for Figure 7 
Patient # Age Diagnosis Current Treatment 
6 42 Metastatic Uterine 
Leiomyosarcoma 
Yondelis 
8 44 Metastatic Myxoid 
Liposarcoma 
Yondelis 
9 44 Metastatic Mixed 
Mullerian tumor 
Yondelis 
10 48 Metastatic Synovial 
Sarcoma 
Temsirolimus 
14 41 Metastatic Pleomorphic 
Sarcoma 
Yondelis 
15 52 Metastatic Myxoid 
Liposarcoma 
Yondelis 
16 48 Metastatic Myxoid 
Liposarcoma 
Yondelis 
17 55 Metastatic 
Leiomyosarcoma 
Yondelis 






In vitro tumor-exposed CFPs promote HT-1080 fibrosarcoma invasion and display 
altered cytokine profiles compared to control CFPs. 
 Our in vitro data with CM from patients with STS suggests CFP-derived 
fibroblasts promote HT-1080 proliferation, migration, and invasion over αMEM, although 
not all patient CFPs show a significant difference in ability to do so compared to normal 
control CFPs (Figure 7).  A complication of these studies was the use of the HT-1080 
fibrosarcoma cell line for assays with STS patients that had other types of STS, meaning 
the HT-1080 fibrosarcoma tumor cell type used in the previous assays did not match the 
tumors of the individual STS patients.  The rarity and heterogeneity (over 100 different 
subtypes) of STS means there are few cell lines available and cell lines have not been 
created for each STS subtype.  Thus, we aimed to create an in vitro culture method for 
generating tumor-exposed CFPs (an in vitro analogue of CFPs derived from patients 
with STS) that could then be used in proliferation and invasion assays with tumor cells of 
the same subtype to which the CFPs were exposed to.  
Peripheral blood was obtained from normal control subjects without any known 
malignancies and cultured for growth of CFP-derived fibroblasts in either αMEM 
supplemented with 20% fetal bovine serum and penicillin streptomycin (normal control) 
or HT-1080 CM supplemented with 20% fetal bovine serum and penicillin streptomycin 
(tumor-exposed). Normal control and tumor-exposed CFP-derived fibroblasts were 
cultured in their designated media for up to 15 days with media renewal every 3 days 
after the first week of culture.  CM was then collected from normal control and tumor-
exposed CFPs for use in proliferation, invasion, and cytokine array assays (Figure 8).  
Because CFPs are present in the peripheral blood, our chosen method for generating in 
vitro tumor-exposed CFPs was co-culture of CFPs with tumor CM, rather than direct cell-
to-cell contact with tumor cells as may be important for studies of tumor-stroma 
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interactions.  Exposure to tumor CM is therefore a better model for our studies in order 
to study CFP response to tumor secreted proteins in the peripheral blood. 
 Our data indicated that tumor-exposed CFP CM promoted HT-1080 tumor cell 
proliferation over αMEM and 1% FBS positive control, although not significantly over 
normal control CFP CM.  Tumor-exposed CFP CM was further found to promote HT-
1080 invasion over normal control CFPs (2.25 fold increase), implicating that CFPs may 
play a more important role in tumor invasiveness through production of matrix degrading 
proteins than through secretion of growth factors involved in tumor cell proliferation.   
Cytokine array analysis revealed an altered cytokine profile of tumor-exposed 
CFP CM compared to normal control CFP CM (Figure 9). Factors found to be increased 
more than 2 fold in tumor-exposed CFP CM included CD14, Complement Factor D, 
EMMPRIN, CXCL5, IL-8, MCP-1, MIF, Serpin E1, and uPAR, with MCP-1 having the 
highest expression. Additionally, RANTES, although lowly expressed in control CFPs, 
was found to be decreased in tumor-exposed CFP CM. Our cytokine array data suggest 
CFP exposure to tumor secreted factors found in HT-1080 CM alters the CFP 
expression profile.  Tumor crosstalk between cells of the stroma and cells in circulation 
is known to play an important role in tumor progression.  Our data implicate this 

















Figure 8. In vitro generation of tumor-exposed CFPs. Tumor-exposed CFPs were 
generated in vitro by culturing normal CFPs in HT-1080 fibrosarcoma conditioned media 
(CM) supplemented with 20% FBS for 15 days with media renewal every 3 days after 
the first week of culture.  Control CFPs were cultured in αMEM supplemented with 20% 
FBS for 15 days with media renewal every 3 days after the first week of culture. Media 
was then removed from cells, and cells were serum starved for 24 hours to obtain 
conditioned media to be used in subsequent assays.  
HT-1080 CM 
supplemented 
with 20% FBS 
αMEM 
supplemented 
with 20% FBS 
CFPs cultured in designated 
media for 15 days, with media 
renewal every 3 days after the 
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Figure 9. In vitro generated tumor-exposed CFPs promote invasion of tumor cells 
along with an altered cytokine profile compared to control CFPs. Conditioned 
media (CM) was collected from normal control CFP-derived fibroblasts (Norm CFP) or 
from norm CFP-derived fibroblasts exposed to HT-1080 CM (Tumor-exposed CFP) and 
examined in vitro for ability to promote HT-1080 fibrosarcoma proliferation after 24, 48 



































































































fibronectin matrigel coated transwells after 22 hours. 1% FBS served as positive control. 
CM from Norm Control CFP and Tumor-exposed CFPs was subjected to cytokine array 
analysis and average pixel density was analyzed by ImageJ software (C).  Fold change 
of average pixel density of Tumor-exposed CFP over Norm CFP CM was then assessed 
(D). * P<0.05 compared to normal control CFP CM (A,B).  
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Section 5: Discussion 
Cancer-associated fibroblasts (CAFs), have been shown to promote tumor 
progression in numerous tumor types, although they have not be investigated in STS. 
CAFs accelerate tumor progression by stimulating angiogenesis, cancer cell growth, 
invasion and metastasis, and through evasion of the immune response.  CAFs 
implement these effects by production of various growth factors, matrix 
metalloproteinases (such as MMP9 which degrades collagen and fibronectin, allowing 
the tumor cell to transverse the basement membrane), and through production of 
chemokines and cytokines.  Our lab has shown that CFPs, a precursor to CAFs, 
contribute to tumor growth and migrate in response to monocyte chemoattractant 
protein-1 (MCP-1), suggesting that CFPs may play a direct role in promoting the 
progression and metastasis of solid tumors14.  It was, therefore, the goal of our study to 
test whether CFP-derived fibroblasts play a functional role in soft tissue sarcoma 
metastasis through production of specific chemokine, cytokine, and growth factors 
involved in promoting the proliferation, migration, and invasion of sarcoma cells. 
 Our data suggest that CFPs from both patients with STS and normal control 
subjects promoted sarcoma tumor cell proliferation, migration, and invasion over αMEM 
(control media). CFPs from some patients with STS further showed enhanced ability to 
promote tumor cell proliferation, migration, and invasion over normal control CFPs.  
CFPs from the three patients with metastatic myxoid liposarcoma further displayed 
enhanced ability to promote HT-1080 proliferation over normal control subjects, with one 
of these patients (patient 8) showing an appreciable enhancement even over other STS 
patients. Because we often receive a limited amount of peripheral blood from patients, 
not all patients had enough cells to conduct proliferation, migration, and invasion assays.  
However, CFPs for patients 8, 9, and 10 were able to be analyzed for ability to promote 
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HT-1080 proliferation, migration, and invasion. Patient 8, with metastatic myxoid 
liposarcoma and Yondelis treatment showed increased ability to promote proliferation 
and migration over normal controls.  Patient 9, with metastatic mixed mullerian tumor, 
showed increased ability to promote migration over normal controls, whereas patient 10, 
with metastatic synovial sarcoma and Temsirolimus treatment did not show a significant 
increase over normal control subjects in any assay.  Acquiring more patients with 
varying STS subtypes and chemotherapeutic treatments would allow us to analyze 
whether these effects are subtype or treatment related and allow us to determine 
whether these results correlate with patient prognosis. 
 A complication of our studies using the HT-1080 fibrosarcoma cell line for 
proliferation, migration, and invasion assays was that STS patients had STS subtypes 
that did not match that of the HT-1080 fibrosarcoma tumor cell being used in the 
previous assays. Thus, we aimed to create an in vitro culture method for generating 
tumor-exposed CFPs. Our in vitro generated tumor-exposed CFPs displayed an 
increased potential to promote tumor proliferation and invasion, with invasive ability 
being significant over normal control CFPs. The in vitro generated tumor-exposed CFPs 
revealed altered cytokine profiles compared to normal control CFPs with many proteins 
of interest in regards to tumor progression increased over that of normal control CFPs. 
Cytokines including EMMPRIN, MCP-1, IL-8, uPAR, and Serpin E1 showed increased 
expression in tumor-exposed CFPs compared to normal control CFPs. EMMPRIN is 
known to induce MMP synthesis by both tumor cells and fibroblasts, potentiating tumor 
cell invasiveness in the tumor microenvironment and leading to the induction of 
angiogenesis through stimulation of VEGF production99. The induction of MMP synthesis 
through EMMPRIN may correlate with our invasion studies where tumor-exposed CFP 
ability to promote tumor invasion was significantly increased compared to control CFPs. 
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EMMPRIN has further been implicated as a prognostic marker for osteosarcoma when 
combined with MMP expression100. MCP-1 was found to be an important cytokine 
involved in trafficking of HSC-derived CFPs in our lab’s previous murine tumor studies14. 
These studies revealed that CFP migration toward tumor conditioned media was MCP-1 
dependent and it was shown that MCP-1 inhibition blocked tumor progression in vivo. IL-
8 is a proinflammatory cytokine and its expression has been shown to correlate with 
tumorigenicity, angiogenesis, and metastasis in numerous in vivo tumor models101–103. 
UPAR plays an important role in tumorigenicity, ECM degradation, and angiogenesis104. 
Studies have demonstrated that co-detection of uPAR in tumor tissue and serum 
correlated with poor prognosis in patients with STS105. Serpin E1 is an inhibitor of tissue 
plasminogen activator and urokinase (uPA, an ECM degrading protease). Human 
fibrosarcoma cells transfected with Serpin E1 cDNA and then injected into the tail vein of 
mice led to increased number and incidence of lung colonization106. Furthermore, it was 
found that UPAR and Serpin E1 are induced in migratory cells and focalize to the 
leading edge where they function in matrix restructuring and migration107. Therefore, our 
data may indicate that after exposure to tumor cells, CFPs have enhanced abilities to 
function in migration and matrix restructuring. Overall, our data suggest CFPs from 
patients with STS promote tumor progression and in vitro generated tumor-exposed 





Chapter 6: Conclusions and Future Directions 
Soft tissue sarcomas (STS) are rare, heterogeneous malignant tumors of 
mesenchymal origin that manifest in the connective tissues. The most lethal aspect of 
sarcomas is their propensity for hematogenous dissemination leading to metastatic 
disease.  After development of distant metastases, the median survival for patients with 
STS is merely 11 to 15 months1,2.  Therefore, gaining a better understanding of the 
metastatic environment is essential to developing new therapies.   
The tumor microenvironment  has been implicated as an essential component for 
metastatic progression and one of the most prominent cell types of the tumor 
microenvironment is the cancer-associated fibroblast (CAF)3,4. Studies clearly show the 
importance of CAFs in tumor advancement; however, their origins have not been 
conclusively determined7–12. Our lab previously demonstrated a novel hematopoietic stem 
cells (HSCs) source for CAFs and their blood precursors, circulating fibroblast precursors 
(CFPs)13. Our lab further revealed that murine CFPs were present in peripheral blood, 
found in vivo in the tumor stroma, and increased with increasing tumor burden, potentially 
implicating CFPs in the progression of solid tumors14. Additionally, our lab revealed a HSC 
origin for human CFPs15. The function of human CFPs in tumor metastasis, specifically 
STS, however, had yet to be established. It was therefore, the goal of this study to isolate 
and evaluate the peripheral blood of patients with STS in order to characterize CFPs in 
these patients and determine their role in promoting STS tumor progression.  
Our data indicated that our isolation technique for obtaining the non-adherent 
population of MNCs was sufficient for enriching for CD45+ HSC-derived cells and that 
this enrichment was enhanced with increasing culture time (from 2 hrs to 20 hrs). 
Immunohistochemical analysis of the cultured non-adherent MNC population from the 
peripheral blood of patients with metastatic STS and normal control subjects revealed 
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CFPs were present in this fraction of human peripheral blood, displaying fibroblastic 
marker expression for collagen 1 (Col I), alpha smooth muscle actin (αSMA), and 
vimentin. In order to quantify CFPs in the peripheral blood of patients with STS, flow 
cytometric analysis of CD45+ DDR2+ cells (CFPs) was performed. Although there was no 
significant difference in the average percentage of CFPs present within the peripheral 
blood of patients with STS compared to normal control subjects, changes in percentage 
of CFPs were observed between individual STS patients with different treatment 
regimens and disease stages.  The patient with metastatic disease without 
chemotherapeutic treatment showed significant increase in percentage of CFPs over 
other patients and control. Furthermore, patients with metastatic STS were shown to 
have a higher percentage of CFPs compared to a patient with non-metastatic STS.  This 
data may suggest chemotherapeutic treatment functions in part by suppressing the CFP 
population and may also implicate percentage of CFPs as a biomarker for response to 
chemotherapeutic treatment.  
We then went on to test whether CFP-derived fibroblasts played a functional role 
in STS metastasis through the promotion of sarcoma cell proliferation, migration, and 
invasion via production of specific chemokine, cytokine, and/or growth factors.  Our data 
suggest that CFPs from both patients with STS and normal control subjects promoted 
tumor cell proliferation, migration, and invasion over αMEM (control media). CFPs from 
some patients with STS further showed enhanced ability to promote tumor cell 
proliferation, migration, and invasion over normal control CFPs.  CFPs from patients with 
metastatic myxoid liposarcoma (n=3) further displayed enhanced ability to promote HT-
1080 proliferation over normal control subjects, with one of these patients (patient 8) 
showing an appreciable enhancement even over other STS patients.  
61 
 
 In vitro generated tumor-exposed CFPs additionally displayed an increased 
potential to promote tumor proliferation and invasion, with invasive ability being 
significant over normal control CFPs. In vitro generated tumor-exposed CFPs revealed 
altered cytokine profiles compared to normal control CFPs with increased expression of 
cytokines including EMMPRIN, MCP-1, IL-8, MIF, and uPAR, all known to play important 
roles in tumor advancement. Together, our data demonstrate that CFPs promote the 
invasive/metastatic potential of STS cells and suggest this is affected, at least in part, by 
paracrine factors. 
Future directions for the continued characterization of CFPs in patients with STS 
should include increased STS patient accrual in order to identify differences in 
percentage of CFPs based upon subtype, tumor stage (metastatic vs. non-metastatic), 
and treatment.  This knowledge will further enhance our understanding of the role of 
CFPs in tumor progression and allow us to determine whether percentage of CFPs in 
the peripheral blood correlates with STS subtype, tumor stage, and or treatment and if 
this may be a predictor of patient response to chemotherapy. This knowledge would be 
especially efficacious in the treatment of patients with STS because chemotherapeutic 
agents have exhibited varied response rates, making it a challenge for physicians to 
identify which patients will benefit from treatment.  Thus, it may spare patients who 
would not respond to chemotherapy from possible toxicity-related side effects of 
treatment. Additionally, it would be beneficial to examine STS tumor sections in primary 
tumor and metastatic sites and identify presence of CFPs to determine whether CFP 
numbers at the tumor site correspond with numbers of circulating CFPs in the peripheral 
blood of patients with STS and whether these numbers are indicative of prognosis.  
Tumor samples from patients with STS, as examined through Oncomine data, have 
been shown to express DDR2 (one of the markers of a CFP), potentially implicating it as 
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an important factor in this disease, justifying DDR2 as a focus for future studies108–113. 
Further in vitro analysis of CFP function may also be performed to assess cytokine role 
in tumor progression.  For example, we saw increased EMMPRIN, MCP-1, IL-8, MIF, 
and uPAR expression in our in vitro tumor-exposed CFPs compared to control CFPs and 
through specifically blocking these cytokines in vitro, we may determine their role in 
promoting sarcoma cell proliferation, migration, and invasion, potentially identifying 
factors that could be blocked in the clinical setting during therapeutic treatment.  
The end goal of these studies is improved outcome for patients with metastatic 
STS. We hope that by better characterizing CFPs and their functional roles in patients 
with STS, we may identify markers of disease progression that will assist clinicians in 
determining which patients will possibly benefit from chemotherapeutic treatment, while 
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